Subcutaneous injection of evolocumab
Sponsors
Kanazawa University Hospital
Conditions
Heterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemia
Unknown Phase
Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Active, not recruitingJPRN-UMIN000022603
Start: 2016-06-06Target: 2Updated: 2026-06-29
Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Active, not recruitingJPRN-UMIN000022604
Start: 2016-06-06Target: 10Updated: 2026-06-29